Articles:
Methodological Issues in Clinical Drug Development for Essential Tremor
Michael A. Carranza; Madeline R. Snyder; Rodger J. Elble; Angelique E. Boutzoukas; Theresa A. Zesiewicz
Downloads:
- Title:
- Methodological Issues in Clinical Drug Development for Essential Tremor
- Author(s):
-
Carranza, Michael A.
Snyder, Madeline R.
Elble, Rodger J.
Boutzoukas, Angelique E.
Zesiewicz, Theresa A. - Date:
- 2012
- Type:
- Articles
- Department:
- Center for Parkinson's Disease and Other Movement Disorders
- Volume:
- 2
- Permanent URL:
- http://hdl.handle.net/10022/AC:P:14473
- Book/Journal Title:
- Tremor and Other Hyperkinetic Movements
- Abstract:
- Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET.
- Subject(s):
- Neurosciences
- Item views:
- 50